FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2107321252> ?p ?o ?g. }

• W2107321252 endingPage "3276" @default.
• W2107321252 startingPage "3268" @default.
• W2107321252 abstract "Background and Purpose— Multiple approaches are being studied to enhance the rate of thrombolysis for acute ischemic stroke. Treatment of myocardial infarction with a combination of a reduced-dose fibrinolytic agent and a glycoprotein (GP) IIb/IIIa receptor antagonist has been shown to improve the rate of recanalization versus fibrinolysis alone. The c ombined approach to l ysis utilizing e ptifibatide a nd r ecombinant tissue-type plasminogen activator (rt-PA) (CLEAR) stroke trial assessed the safety of treating acute ischemic stroke patients within 3 hours of symptom onset with this combination. Methods— The CLEAR trial was a National Institutes of Health/National Institute of Neurological Disorders and Stroke–funded multicenter, double-blind, randomized, dose-escalation and safety study. Patients were randomized 3:1 to either low-dose rt-PA (tier 1=0.3 mg/kg, tier 2=0.45 mg/kg) plus eptifibatide (75 μg/kg bolus followed by 0.75 μg/kg per min infusion for 2 hours) or standard-dose rt-PA (0.9 mg/kg). The primary safety end point was the incidence of symptomatic intracerebral hemorrhage within 36 hours. Secondary analyses were performed regarding clinical efficacy. Results— Ninety-four patients (40 in tier 1 and 54 in tier 2) were enrolled. The combination group of the 2 dose tiers (n=69) had a median age of 71 years and a median baseline National Institutes of Health Stroke Scale (NIHSS) score of 14, and the standard-dose rt-PA group (n=25) had a median age of 61 years and a median baseline NIHSS score of 10 ( P =0.01 for NIHSS score). Fifty-two (75%) of the combination treatment group and 24 (96%) of the standard treatment group had a baseline modified Rankin scale score of 0 ( P =0.04). There was 1 (1.4%; 95% CI, 0% to 4.3%) symptomatic intracranial hemorrhage in the combination group and 2 (8.0%; 95% CI, 0% to 19.2%) in the rt-PA–only arm ( P =0.17). During randomization in tier 2, a review by the independent data safety monitoring board demonstrated that the safety profile of combination therapy at the tier 2 doses was such that further enrollment was statistically unlikely to indicate inadequate safety for the combination treatment group, the ultimate outcome of the study. Thus, the study was halted. There was a trend toward increased clinical efficacy of standard-dose rt-PA compared with the combination treatment group. Conclusions— The safety of the combination of reduced-dose rt-PA plus eptifibatide justifies further dose-ranging trials in acute ischemic stroke." @default.
• W2107321252 created "2016-06-24" @default.
• W2107321252 creator A5006246283 @default.
• W2107321252 creator A5007746022 @default.
• W2107321252 creator A5009170752 @default.
• W2107321252 creator A5010431596 @default.
• W2107321252 creator A5010722813 @default.
• W2107321252 creator A5015193212 @default.
• W2107321252 creator A5022787061 @default.
• W2107321252 creator A5028127034 @default.
• W2107321252 creator A5048905061 @default.
• W2107321252 creator A5062220434 @default.
• W2107321252 creator A5063432191 @default.
• W2107321252 creator A5063673987 @default.
• W2107321252 creator A5068433832 @default.
• W2107321252 creator A5077001256 @default.
• W2107321252 creator A5077829407 @default.
• W2107321252 creator A5079955678 @default.
• W2107321252 creator A5083232394 @default.
• W2107321252 creator A5083533557 @default.
• W2107321252 creator A5083629600 @default.
• W2107321252 creator A5086708867 @default.
• W2107321252 creator A5090972492 @default.
• W2107321252 date "2008-12-01" @default.
• W2107321252 modified "2023-10-15" @default.
• W2107321252 title "The <i>C</i> ombined Approach to <i>L</i> ysis Utilizing <i>E</i> ptifibatide <i>a</i> nd <i>r</i> t-PA in Acute Ischemic Stroke" @default.
• W2107321252 cites W1971822850 @default.
• W2107321252 cites W1976425448 @default.
• W2107321252 cites W1998589931 @default.
• W2107321252 cites W1998796974 @default.
• W2107321252 cites W2000901881 @default.
• W2107321252 cites W2028272526 @default.
• W2107321252 cites W2085771291 @default.
• W2107321252 cites W2107272221 @default.
• W2107321252 cites W2111977341 @default.
• W2107321252 cites W2142848477 @default.
• W2107321252 cites W2168079615 @default.
• W2107321252 cites W2281862598 @default.
• W2107321252 cites W2292308933 @default.
• W2107321252 cites W4256202725 @default.
• W2107321252 doi "https://doi.org/10.1161/strokeaha.108.517656" @default.
• W2107321252 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2588546" @default.
• W2107321252 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18772447" @default.
• W2107321252 hasPublicationYear "2008" @default.
• W2107321252 type Work @default.
• W2107321252 sameAs 2107321252 @default.
• W2107321252 citedByCount "147" @default.
• W2107321252 countsByYear W21073212522012 @default.
• W2107321252 countsByYear W21073212522013 @default.
• W2107321252 countsByYear W21073212522014 @default.
• W2107321252 countsByYear W21073212522015 @default.
• W2107321252 countsByYear W21073212522016 @default.
• W2107321252 countsByYear W21073212522017 @default.
• W2107321252 countsByYear W21073212522018 @default.
• W2107321252 countsByYear W21073212522019 @default.
• W2107321252 countsByYear W21073212522020 @default.
• W2107321252 countsByYear W21073212522021 @default.
• W2107321252 countsByYear W21073212522022 @default.
• W2107321252 countsByYear W21073212522023 @default.
• W2107321252 crossrefType "journal-article" @default.
• W2107321252 hasAuthorship W2107321252A5006246283 @default.
• W2107321252 hasAuthorship W2107321252A5007746022 @default.
• W2107321252 hasAuthorship W2107321252A5009170752 @default.
• W2107321252 hasAuthorship W2107321252A5010431596 @default.
• W2107321252 hasAuthorship W2107321252A5010722813 @default.
• W2107321252 hasAuthorship W2107321252A5015193212 @default.
• W2107321252 hasAuthorship W2107321252A5022787061 @default.
• W2107321252 hasAuthorship W2107321252A5028127034 @default.
• W2107321252 hasAuthorship W2107321252A5048905061 @default.
• W2107321252 hasAuthorship W2107321252A5062220434 @default.
• W2107321252 hasAuthorship W2107321252A5063432191 @default.
• W2107321252 hasAuthorship W2107321252A5063673987 @default.
• W2107321252 hasAuthorship W2107321252A5068433832 @default.
• W2107321252 hasAuthorship W2107321252A5077001256 @default.
• W2107321252 hasAuthorship W2107321252A5077829407 @default.
• W2107321252 hasAuthorship W2107321252A5079955678 @default.
• W2107321252 hasAuthorship W2107321252A5083232394 @default.
• W2107321252 hasAuthorship W2107321252A5083533557 @default.
• W2107321252 hasAuthorship W2107321252A5083629600 @default.
• W2107321252 hasAuthorship W2107321252A5086708867 @default.
• W2107321252 hasAuthorship W2107321252A5090972492 @default.
• W2107321252 hasBestOaLocation W21073212521 @default.
• W2107321252 hasConcept C126322002 @default.
• W2107321252 hasConcept C127413603 @default.
• W2107321252 hasConcept C141071460 @default.
• W2107321252 hasConcept C168563851 @default.
• W2107321252 hasConcept C203092338 @default.
• W2107321252 hasConcept C2776572282 @default.
• W2107321252 hasConcept C2779581417 @default.
• W2107321252 hasConcept C2780400711 @default.
• W2107321252 hasConcept C2780645631 @default.
• W2107321252 hasConcept C2781056559 @default.
• W2107321252 hasConcept C2909817843 @default.
• W2107321252 hasConcept C42219234 @default.
• W2107321252 hasConcept C43376680 @default.
• W2107321252 hasConcept C500558357 @default.
• W2107321252 hasConcept C71924100 @default.
• W2107321252 hasConcept C78519656 @default.

• next